Insider · CIK 0001704317

Coric Vlad

Reports to the SEC for 6 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001704317

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-05	RPRXRoyalty Pharma plcA Award	Director	AAward	+4,545 sh	—	—	15,343
2026-02-27	BHVNBiohaven Ltd. · Stock Options (Right to buy)A Award	Director, Chief Executive Officer	AAward	+550K sh	—	—	550,000
2026-02-05	MANEVeradermics, Inc · Series A Convertible Preferred StockC Conversion	Director	CConversion	−33.7K sh	—	—	0
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+117K sh	—	—	129,939
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+78.1K sh	—	—	260,575
2026-02-05	MANEVeradermics, Inc · Series C Convertible Preferred StockC Conversion	Director	CConversion	−78.1K sh	—	—	0
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+149K sh	—	—	182,500
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+149K sh	—	—	182,500
2026-02-05	MANEVeradermics, Inc · Series C Convertible Preferred StockC Conversion	Director	CConversion	−117K sh	—	—	0
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+78.1K sh	—	—	260,575
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+33.7K sh	—	—	33,706
2026-02-05	MANEVeradermics, IncP Purchase	Director	PPurchase	+58.8K sh	$17.00	+$1M	319,398
2026-02-05	MANEVeradermics, IncP Purchase	Director	PPurchase	+58.8K sh	$17.00	+$1M	319,398
2026-02-05	MANEVeradermics, Inc · Series B Convertible Preferred StockC Conversion	Director	CConversion	−149K sh	—	—	0
2026-02-05	MANEVeradermics, Inc · Series B Convertible Preferred StockC Conversion	Director	CConversion	−149K sh	—	—	0
2026-02-05	MANEVeradermics, Inc · Series C Convertible Preferred StockC Conversion	Director	CConversion	−78.1K sh	—	—	0
2026-02-05	MANEVeradermics, IncC Conversion	Director	CConversion	+33.7K sh	—	—	33,706
2026-02-05	MANEVeradermics, Inc · Series A Convertible Preferred StockC Conversion	Director	CConversion	−33.7K sh	—	—	0
2026-02-03	MANEVeradermics, Inc · Stock Option (Right to Buy)A Award	Director	AAward	+51.5K sh	—	—	51,525
2026-01-05	BHVNBiohaven Ltd.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−7,430 sh	$9.93	−$73.8K	1,803,968
2026-01-05	BHVNBiohaven Ltd.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+14.3K sh	—	—	1,811,398
2026-01-05	BHVNBiohaven Ltd. · Restricted Share Unit AwardM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.3K sh	—	—	28,500
2025-11-13	BHVNBiohaven Ltd.P Purchase	Director, Chief Executive Officer	PPurchase	+333K sh	$7.50	+$2.5M	740,546
2025-11-13	BHVNBiohaven Ltd.P Purchase	Director, Chief Executive Officer	PPurchase	+333K sh	$7.50	+$2.5M	1,195,275
2025-05-13	RPRXRoyalty Pharma plcA Award	Director	AAward	+7,614 sh	—	—	10,798
2025-04-21	RPRXRoyalty Pharma plcA Award	Director	AAward	+3,184 sh	—	—	3,184
2025-02-06	Revance Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2025-02-04	Revance Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−5,784 sh	$3.65	−$21.1K	15,000
2025-01-05	BHVNBiohaven Ltd.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−6,805 sh	$38.64	−$263K	1,796,604
2025-01-05	BHVNBiohaven Ltd.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+14.3K sh	—	—	1,803,409
2025-01-05	BHVNBiohaven Ltd. · Stock Options (Right to buy)A Award	Director, Chief Executive Officer	AAward	+343K sh	—	—	343,000
2025-01-05	BHVNBiohaven Ltd. · Restricted Share Unit AwardA Award	Director, Chief Executive Officer	AAward	+57K sh	—	—	57,000
2025-01-05	BHVNBiohaven Ltd. · Restricted Share Unit AwardM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.3K sh	—	—	42,750
2024-10-02	BHVNBiohaven Ltd.P Purchase	Director, Chief Executive Officer	PPurchase	+21.1K sh	$47.50	+$1M	861,942
2024-05-01	Revance Therapeutics, Inc.A Award	Director	AAward	+15K sh	—	—	20,784
2024-05-01	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	Director	AAward	+23.5K sh	—	—	23,458
2024-04-22	BHVNBiohaven Ltd.P Purchase	Director, Chief Executive Officer	PPurchase	+122K sh	$41.00	+$5M	1,788,417
2024-04-05	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+231 sh	—	—	407,213
2024-04-05	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+231 sh	—	—	840,890
2024-04-05	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+232 sh	—	—	1,666,466
2024-03-08	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+2,155 sh	—	—	840,659
2024-03-08	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+2,162 sh	—	—	1,666,234
2024-03-08	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+2,155 sh	—	—	406,982
2024-01-08	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+5,384 sh	—	—	404,827
2024-01-08	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+5,384 sh	—	—	838,504
2024-01-08	BHVNBiohaven Ltd.A Award	Director, Chief Executive Officer	AAward	+5,400 sh	—	—	1,662,431
2024-01-02	BHVNBiohaven Ltd. · Stock Options (Right to buy)A Award	Director, Chief Executive Officer	AAward	+275K sh	—	—	275,000
2023-11-02	BHVNBiohaven Ltd. · Stock Options (Right to buy)A Award	Director, Chief Executive Officer	AAward	+225K sh	—	—	225,000
2023-10-05	BHVNBiohaven Ltd.P Purchase	Director, Chief Executive Officer	PPurchase	+341K sh	$22.00	+$7.5M	833,120
2023-10-05	BHVNBiohaven Ltd.P Purchase	Director, Chief Executive Officer	PPurchase	+114K sh	$22.00	+$2.5M	1,657,031

Recent filings

Accepted (ET)
Jun 84
Coric Vlad0001704317-26-000006
SEC(opens sec.gov)
Mar 34
Coric Vlad0001704317-26-000004
SEC(opens sec.gov)
Feb 54
Coric Vlad0001628280-26-005907
SEC(opens sec.gov)
Jan 74
Coric Vlad0001704317-26-000002
SEC(opens sec.gov)

Companies

Address

C/O ROYALTY PHARMA PLC 110 E. 59TH STREET

NEW YORK, NY, 10022